SecBot SecBot
COURT-RULING ·Filed May 28, 2026

PODD

INSULET CORP
BEARISH
Impact 7/10
Horizonweeks Processed5mo ago CourtCourt Ruling · courtlistener.com
Court ruling (appellate)
Actionable Insight ▼ Bearish

This ruling removes a major competitive barrier for EOFlow, which can now commercialize EOPatch 2 without the permanent injunction. For PODD holders, this increases competitive pressure in the insulin patch pump market and eliminates a significant IP victory. Monitor for EOFlow's market entry plans and any potential appeal by Insulet to the Supreme Court (unlikely given Federal Circuit's clear ruling on statute of limitations).

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$141.98
T+0 close · May 28, 2026 · via day close
Latest settled
+4.18%
T+60 · $147.92
Vs SPY
+2.71%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 28 $141.98entry
  2. T+1 · 6mo ago +1.42%α +1.18% · $143.99
  3. T+5 · 6mo ago +0.93%α +0.97% · $143.30
  4. T+20 · 5mo ago +8.34%α +11.03% · $153.82
  5. T+60 · 3mo ago +4.18%α +2.71% · $147.92
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The Federal Circuit reversed the district court's judgment and permanent injunction against EOFlow, holding that Insulet's trade secret misappropriation claim under the Defend Trade Secrets Act was time-barred because Insulet knew or should have known of the misappropriation before August 3, 2020 (three years before filing suit). The court found undisputed evidence that Insulet had knowledge of EOFlow's access to its trade secrets through a former employee and of striking similarities between the Omnipod and EOPatch 2 by early 2019, triggering the three-year statute of limitations. This ruling vacates the $59.4 million in damages (after reduction) and the permanent injunction that barred EOFlow from commercializing products using Insulet's trade secrets, removing a major overhang on EOFlow's ability to compete in the insulin patch pump market.

Court Ruling Details

Ruling Date
May 28, 2026
Court
United States Court of Appeals for the Federal Circuit
Court Level
Appellate
Judge
Dyk
Case Type
ip trade secret
Ruling Type
final judgment
Outcome
LOSS: ruling against this company
Precedent Risk
MEDIUM

Key Facts

  • Federal Circuit reversed district court's judgment and permanent injunction against EOFlow in Insulet's trade secret misappropriation case
  • Court held Insulet's DTSA claim was time-barred because Insulet knew or should have known of misappropriation before August 3, 2020
  • Jury had awarded $170M compensatory and $282M exemplary damages, later reduced to $25.8M compensatory and $33.6M exemplary to avoid double recovery with injunction
  • Permanent injunction had barred EOFlow from commercializing products using Insulet's trade secrets worldwide
  • Court applied access-plus-similarity framework: knowledge that former employee with trade secret access worked for competitor on similar product starts limitations clock
  • Insulet had internal emails from March 2019 noting former employees worked on EOPatch 2, and employees described EOPatch 2 as 'cloned our product' after June 2018 ADA conference
  • Dissenting opinion argued majority improperly substituted its fact-finding for the jury's and conflated discovery rule with inquiry-notice standard

Financial Impact

Vacated $59.4M in damages (after reduction) and permanent injunction; Insulet loses trade secret protection and competitive moat against EOFlow's EOPatch 2

revenuecompetitive_positionip_protection

Risk Factors

  • Insulet may seek Supreme Court review, though certiorari is unlikely on a statute-of-limitations ruling
  • EOFlow's EOPatch 2 could gain market share in Europe and South Korea, pressuring Omnipod sales
  • Loss of trade secret protection may encourage other competitors to enter the patch pump market
  • Insulet's patent claims were dismissed without prejudice but are likely time-barred, leaving no remaining IP claims against EOFlow

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
85% bullish (34 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-3ayo3elp-PODD

Track record

11 reports on PODD

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $152.48 Now $145.29 −4.72% settles Feb 11
  3. Nov 4, 202612d ago 8-K Bullish 6/10 Entry $165.02 Now $145.29 −11.96% settles Feb 2
  4. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $148.93 Now $145.29 −2.44% settles Jan 26
  5. Oct 23, 202624d ago Institutional Cluster Neutral 3/10 Entry $149.01 Now $145.29 −2.50% settles Jan 21
  6. Sep 21, 20268w ago 8-K Bullish 6/10 Entry $139.38 Now $145.29 +4.24% settles Dec 16
  7. Aug 5, 202614w ago 8-K Mixed 5/10 Entry $132.30 to $152.50 Now $145.29 +9.82% ▲ +15.26% +15.32% vs SPY
  8. Jul 24, 202616w ago Institutional Cluster Bearish 5/10 Entry $163.26 to $141.96 Now $145.29 +11.01% ▲ +13.05% +16.77% vs SPY
  9. May 28, 202624w ago Court Ruling Bearish 7/10 Viewing Entry $141.98 to $147.92 Now $145.29 −2.33% ▼ −4.18% −2.71% vs SPY
  10. May 6, 202627w ago 8-K Bullish 7/10 Entry $150.52 to $165.68 Now $145.29 −3.48% ▲ +10.07% +9.00% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Wed (11h 21m)

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · courtlistener.com Report published May 28, 2026